Skip to content

Alterations in ventricular remodeling after application of semaglutide in patients with acute myocardial infarction (AMI) combined with type 2 diabetes mellitus (T2DM) during the perioperative period of emergency percutaneous coronary intervention

Alterations in ventricular remodeling after application of semaglutide in patients with acute myocardial infarction (AMI) combined with type 2 diabetes mellitus (T2DM) during the perioperative period of emergency percutaneous coronary intervention

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091620
Enrollment
Unknown
Registered
2024-10-31
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction and type 2 diabetes mellitus

Interventions

Sponsors

The First Affiliated Hospital of University of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Between the ages of 18 and 80; (2) Patients definitively diagnosed with acute myocardial infarction and treated with emergency PCI; (3) Patients with a first or previous diagnosis of type 2 diabetes mellitus;

Exclusion criteria

Exclusion criteria: (1) Patients who had been treated with a GLP-1 receptor agonist within 1 week before enrollment; (2) Cardiogenic shock; (3) Active liver disease or hepatic dysfunction; (4) Severe renal dysfunction, defined by estimated glomerular filtration rate <30 ml/min/1.73m2; (5) Diabetic ketoacidosis; (6) Known active infection in the judgment of the Investigator; (7) Severe decrease in gastrointestinal motility, such as gastroparesis; (8) Medullary thyroid carcinoma; (9) Known allergy to semaglutide; (10) Pregnant or breastfeeding women; (11) Anticipated lifespan < 1 year; (12) Inability to comply with follow-up;

Design outcomes

Primary

MeasureTime frame
Assessment of ventricular remodeling by UCG;

Secondary

MeasureTime frame
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) During Hospitalization;Perioperative inflammation levels;Major adverse cardiovascular and cerebrovascular events at 3 months postoperatively;Metabolic biomarker changes at 3 months postoperatively;

Countries

China

Contacts

Public ContactHongwu Chen

The First Affiliated Hospital of University of Science and Technology of China

chenhongwu1975@163.com+86 139 5605 0378

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026